AHOD1331 patient, disease, and treatment characteristics by inclusion/exclusion (whether markers were evaluated)
| Characteristic . | Markers evaluated, n = 206 . | Markers not evaluated, n = 381 . | P value∗ . |
|---|---|---|---|
| Age, y | .139 | ||
| Mean (SD) | 14.8 (3.0) | 15.2 (3.1) | |
| Median (IQR) | 15.4 (13.4-16.9) | 15.7 (13.5-17.3) | |
| Range | 3.4-21.5 | 3.9-22.0 | |
| Sex | .882 | ||
| Female | 96 (47) | 180 (47) | |
| Male | 110 (53) | 201 (53) | |
| Race | .616 | ||
| White | 154 (75) | 282 (75) | |
| Black or African American | 26 (13) | 39 (10) | |
| Asian | 6 (2.9) | 9 (2.4) | |
| Multiple races | 2 (1.0) | 3 (0.8) | |
| Unknown | 7 (3.4) | 25 (6.6) | |
| Not reported | 10 (4.9) | 18 (4.8) | |
| Ethnicity | .264 | ||
| Not Hispanic or Latino | 160 (81) | 277 (77) | |
| Hispanic or Latino | 37 (19) | 82 (23) | |
| Unknown | 9 | 22 | |
| AHOD1331 stratum | .441 | ||
| Stage IIB with bulk | 37 (18) | 84 (22) | |
| Stage IIIB | 36 (17) | 77 (20) | |
| Stage IVA | 64 (31) | 103 (27) | |
| Stage IVB | 69 (33) | 117 (31) | |
| Histology | .793 | ||
| HL, NOS | 35 (17) | 63 (17) | |
| Lymphocyte rich | 1 (0.5) | 6 (1.6) | |
| Mixed cellularity | 11 (5.3) | 22 (5.8) | |
| Nodular sclerosis | 159 (77) | 290 (76) | |
| Study arm | .942 | ||
| ABVE-PC | 101 (49) | 188 (49) | |
| Bv-AVEPC | 105 (51) | 193 (51) |
| Characteristic . | Markers evaluated, n = 206 . | Markers not evaluated, n = 381 . | P value∗ . |
|---|---|---|---|
| Age, y | .139 | ||
| Mean (SD) | 14.8 (3.0) | 15.2 (3.1) | |
| Median (IQR) | 15.4 (13.4-16.9) | 15.7 (13.5-17.3) | |
| Range | 3.4-21.5 | 3.9-22.0 | |
| Sex | .882 | ||
| Female | 96 (47) | 180 (47) | |
| Male | 110 (53) | 201 (53) | |
| Race | .616 | ||
| White | 154 (75) | 282 (75) | |
| Black or African American | 26 (13) | 39 (10) | |
| Asian | 6 (2.9) | 9 (2.4) | |
| Multiple races | 2 (1.0) | 3 (0.8) | |
| Unknown | 7 (3.4) | 25 (6.6) | |
| Not reported | 10 (4.9) | 18 (4.8) | |
| Ethnicity | .264 | ||
| Not Hispanic or Latino | 160 (81) | 277 (77) | |
| Hispanic or Latino | 37 (19) | 82 (23) | |
| Unknown | 9 | 22 | |
| AHOD1331 stratum | .441 | ||
| Stage IIB with bulk | 37 (18) | 84 (22) | |
| Stage IIIB | 36 (17) | 77 (20) | |
| Stage IVA | 64 (31) | 103 (27) | |
| Stage IVB | 69 (33) | 117 (31) | |
| Histology | .793 | ||
| HL, NOS | 35 (17) | 63 (17) | |
| Lymphocyte rich | 1 (0.5) | 6 (1.6) | |
| Mixed cellularity | 11 (5.3) | 22 (5.8) | |
| Nodular sclerosis | 159 (77) | 290 (76) | |
| Study arm | .942 | ||
| ABVE-PC | 101 (49) | 188 (49) | |
| Bv-AVEPC | 105 (51) | 193 (51) |
Data are presented as n (%) unless otherwise specified.
IQR, interquartile range; NOS, not otherwise specified.
Statistical significance was determined using Wilcoxon rank-sum test, Pearson χ2 test, or Fisher exact test.